Trial · NCT04971226
Outcomes33
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Major Molecular Response (MMR) at Week 48 - Ascimimib vs. Investigator Selected TKI | At 48 weeks | The Full Analysis Set (FAS) comprised of all participants to whom study treatment has been assigned by randomization. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Major Molecular Response at Week 96 | at 96 weeks (96 weeks after last patient first dose) | |||
| SECONDARY | Time to Discontinuation of Study Treatment Due to Adverse Events (TTDAE) | 96 weeks after last patient first dose | |||
| SECONDARY | Major Molecular Response at Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | Major Molecular Response by Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | MR4.0 at Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | MR4.5 at All Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | MR4.0 by Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | MR4.5 by All Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | Complete Hematological Response (CHR) at All Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | Complete Hematological Response (CHR) by All Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | Percentage of Participants With Complete Cytogenic Response (CCyR) by Week 48 & Week 96 | By week 48 and by week 96 (48 weeks and 96 weeks after last patient first dose); data collection/analysis is ongoing for the 96 week time point, and the data will be reported later | The Full Analysis Set (FAS) comprised of all participants to whom study treatment has been assigned by randomization and who had a valid bone marrow examination at week 48. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Duration of MMR | Planned total follow-up duration of 5 years | |||
| SECONDARY | Duration of MR4.0 | Planned total follow-up duration of 5 years | |||
| SECONDARY | Duration of MR4.5 | Planned total follow-up duration of 5 years | |||
| SECONDARY | Time to First MMR | Planned total follow-up duration of 5 years | |||
| SECONDARY | Time to First MR4.0 | Planned total follow-up duration of 5 years | |||
| SECONDARY | Time to First MR4.5 | Planned total follow-up duration of 5 years | |||
| SECONDARY | BCR-ABL1≤1% at Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years | |||
| SECONDARY | BCR-ABL1≤1% by Scheduled Data Collection Time Points | Planned total follow-up duration of 5 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04971226/outcomes